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HGPS is an extraordinary disease,
and the generation of patient-derived
iPSCs is a significant milestone. This
step continues the remarkable progress
made in the last few years. After discovery
of the disease-causing gene in 2003, it
only took four years to initiate several
clinical trials. Much has been learnt along
the way about the biology of HGPS and its
relevance to normal aging. The generation
of iPSCs fromHGPS patients now heralds
another wave of rapid progress with
implications for HGPS disease mecha-
nisms, for aging in general, and potentially
as a tool to develop novel strategies to
combat vascular disease.
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A new player in hematopoietic stem cell (HSC)-niche interactions is introduced in this issue of Cell Stem Cell.
Smith-Berdan et al. (2010) demonstrate that Robo4 is involved in HSC engraftment andmobilization and does
so in cooperation with Cxcr4 to guide stem cells to and secure them in the niche.Bone marrow (BM) transplantation has
been used for treatment of hematopoietic
disorders for some fifty years and repre-
sents a paradigm for all future stem cell
therapies. A number of cytokines, espe-
ciallygranulocytecolony-stimulating factor
(G-CSF), are known to mobilize hemato-
poietic stem and progenitor cells (HSPCs)
from their BM niches into the peripheral
blood (PB) (Papayannopoulou and Scad-
den, 2008). Indeed, mobilization is the
preferred method for obtaining transplant-
able HSC. Despite the number of currently
available HSPC mobilizing agents, a
significant number of donors mobilize
poorly. Therefore, identifying novel and
more efficient mobilization approaches is
of paramount clinical importance.
Understanding the molecular frame-
work of how the niche regulates retention
and release of stem cells provides the
ground onwhich to base alternativemobi-
lization strategies. The basic processes of
transplantation are homing to, engraft-
ment in, and retention of HSCs in the
niche. Mobilization may thus be under-6 Cell Stem Cell 8, January 7, 2011 ª2011 Estood as the process of breaking the
bonds of stem cell retention in the BM
niche or enhancement of the existing
means that allow HSCs to enter the PB.
The cellular milieu and molecular mecha-
nisms that mediate these processes are
starting to be revealed but, at best, remain
poorly understood (Garrett and Emerson,
2009). The Cxcr4/Cxcl12 axis has been
identified as critically important in homing,
engraftment, and retention in theBM (Lap-
idot et al., 2005). Previouswork has shown
that the Cxcr4 antagonist AMD3100 can
mobilize both mouse and human HSPCs
and has found use clinically as an adjunct
therapy for poor G-CSF mobilizers (Brox-
meyer et al., 2005). In this issue of Cell
Stem Cell, Smith-Berdan et al. show that
Roundabout 4 (Robo4), a neuronal guid-
ance molecule, regulates engraftment
and mobilization and, in cooperation with
Cxcr4, localizes HSCs to the niche.
Previous profiling studies by the senior
author had revealed that Robo4 was ex-
pressed at high levels in long-term HSCs
(Forsberg et al., 2005). In the presentlsevier Inc.work, the authors show that Robo4
becomes downregulated upon differenti-
ation, consistent with the observations of
Shibata et al., who also demonstrated
that repopulating cells segregated to the
Robo4+ fraction of HSPCs (Shibata et al.,
2009). Notably, Smith-Berdan et al. also
found that Robo4 expressionwas dramat-
ically downregulated in mobilized HSCs.
To determine a functional role for Robo4
in HSCs, the authors investigated Robo4
knockout mice. Robo4/ mice appear
normal but have defects in vascular integ-
rity and angiogenesis (Jones et al., 2008).
An analysis of the stem cell compartments
revealed that Robo4/ mice had a spe-
cific decrease of HSCs in the BM with a
reciprocal increase in PB, suggesting
poor BM retention. Upon transplantation,
Robo4/ HSCs engrafted poorly, but
those that did engraft contributed to a
normal spectrum of blood cell lineages.
In addition, the ability of Robo4/ HSC
tomake spleen colonies was normal, sug-
gesting that the engraftment defect was
likely because of a specific impairment of
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On the basis of these results, the Fors-
berg group hypothesized that Robo4
mediates HSC adhesion to the niche and
that downregulation of Robo4 was a crit-
ical step enabling exit from the niche to
the bloodstream. Consistent with this
idea, the authors predicted that mobiliza-
tion induced by G-CSF treatment would
be elevated in Robo4 null mice. Instead,
they found that Robo4/ HSCs were
delayed in their ability to mobilize in
response to G-CSF. Smith-Berdan et al.
next examined the well-known Cxcr4/
Cxcl12 axis and found that Cxcr4 expres-
sion in HSCs and Cxcl12/Sdf1 expression
in stromal cells was elevated in Robo4/
mice. Thus, a compensatory upregulation
of the Cxcr4/Cxcl12 axis likely explains
why Robo4/ HSCs were slower to
mobilize. Mobilization experiments using
AMD3100, a Cxcr4 antagonist, in con-
junction with G-CSF or as the sole mobili-
zation agent, revealed that HSCs were
specifically mobilized at higher levels in
Robo4/ mice. In order to test whether
inhibition of the Cxcr4/Cxcl12 axis specif-
ically affects stem cell homing, HSCs
were pretreated with AMD3100 before
transplantation. HSCs from both strains
homed less efficiently to BM after
AMD3100 pretreatment but even less so
when lacking Robo4, suggesting that
Robo4 cooperates with Cxcr4 in stem
cell homing. Taken together, these results
suggest that a Robo4 antagonist would
aid in specific mobilization of HSCs into
the bloodstream andmay have a potential
clinical use in combination with otheragents. As such, these experiments pro-
vide enticing evidence for a novel path-
way in stem cell homing, engraftment,
and mobilization from the niche.
The findings of Smith-Brennan et al.
point to an exciting new line of investiga-
tion in stem/niche cell interactions with
many questions to be probed in future
work. At the forefront of these questions
is whether the pattern of Robo4 expres-
sion in human HSCsmimics that in mouse
and whether nongenetic approaches
targeting Robo4 would be useful for
mobilization and purification of HSCs.
Mechanistically, the reciprocal loss of
Robo4 and the upregulation of the
Cxcr4/Cxcl12 axis remain to be defined.
Is there a point where the two pathways
intersect in their downstream signaling?
Of interest, Robo4 is expressed in endo-
thelium and functions in vascular sprout-
ing upon activation by its ligand Slit2. It
will be interesting to determine if Robo4
in this context acts via Slit2 and if there
is an additional coreceptor. Activated
Robo4 also stabilizes the vascular
network through inhibition of endothelial
permeability (Jones et al., 2008). Thus,
how loss of Robo4 affects the endothelial
function will be an important topic to
address in future studies. Finally, where
are the Robo4+ HSC in the BM normally
localized and to where do they home?
Osteoblasts upregulate the expression
of Slit2 after 5-FU treatment (Shibata
et al., 2009), and Slit2 expression has
very recently been found in the extramural
cells surrounding endothelium in devel-
oping mammary tissue (Marlow et al.,
2010). It would be very interesting if Slit2Cell Stem Cexpression were found in the Cxcl12
abundant reticular (CAR) cells that sur-
round endothelium, localize near the
endosteum, and are thought to play a
role in the stem cell niche (Sugiyama
et al., 2006). Indeed, it should be very
revealing to pursue this roundabout way
into and out of the niche.
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